Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease?
Aged
Cystectomy
/ methods
Cystoscopy
Female
Humans
Male
Middle Aged
Multiparametric Magnetic Resonance Imaging
Neoplasm Staging
Predictive Value of Tests
Preoperative Care
Retrospective Studies
Time-to-Treatment
/ statistics & numerical data
Urinary Bladder
/ diagnostic imaging
Urinary Bladder Neoplasms
/ diagnostic imaging
#BladderCancer
#VIRADS
#uroonc
bladder cancer
bladder cancer staging
blcsm
extravesical bladder cancer
multiparametric magnetic resonance imaging
muscle-invasive bladder cancer
radical cystectomy
transurethral resection of bladder tumour
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
13
8
2020
medline:
7
2
2021
entrez:
13
8
2020
Statut:
ppublish
Résumé
(I) To determine Vesical Imaging-Reporting and Data System (VI-RADS) score 5 accuracy in predicting locally advanced bladder cancer (BCa), so as to potentially identify those patients who could avoid the morbidity of deep transurethral resection of bladder tumour (TURBT) in favour of histological sampling-TUR prior to radical cystectomy (RC). (II) To explore the predictive value of VI-RADS score 5 on time-to-cystectomy (TTC) outcomes. We retrospectively reviewed patients' ineligible or refusing cisplatin-based combination neoadjuvant chemotherapy who underwent multiparametric magnetic resonance imaging (mpMRI) of the bladder prior to staging TURBT followed by RC for muscle-invasive BCa. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) were calculated for VI-RADS score 5 vs. score 2-4 cases to assess the accuracy of mpMRI for extravesical BCa detection (≥pT3). VI-RADS score performance was assessed by receiver operating characteristics curve analysis. A Κ statistic was calculated to estimate mpMRI and pathological diagnostic agreement. The risk of delayed TTC (i.e. time from initial BCa diagnosis of >3 months) was assessed using multivariable logistic regression model. A total of 149 T2-T4a, cN0-M0 patients (VI-RADS score 5, n = 39 vs VI-RADS score 2-4, n = 110) were examined. VI-RADS score 5 demonstrated sensitivity, specificity, PPV and NPV, in detecting extravesical disease of 90.2% (95% confidence interval [CI] 84-94.3), 98.1% (95% CI 94-99.6), 94.9% (95% CI 89.6-97.6) and 96.4% (95% CI 91.6-98.6), respectively. The area under the curve was 94.2% (95% CI 88.7-99.7) and inter-reader agreement was excellent (Κ The VI-RADS is valid and reliable in differentiating patients with extravesical disease from those with muscle-confined BCa before TURBT. Detection of VI-RADS score 5 was found to predict significant delay in TTC independently from other clinicopathological features. In the future, higher VI-RADS scores could potentially avoid the morbidity of extensive primary resections in favour of sampling-TUR for histology. Further prospective, larger, and multi-institutional trials are required to validate clinical applicability of our findings.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
610-619Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.
Références
Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int 2008; 102: 1242-6
Richterstetter M, Wullich B, Amann K et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int 2012; 110: E76-9
Suarez-Ibarrola R, Soria F, Abufaraj M et al. Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. BJU Int 2019; 123: 646-50
Dayyani F, Hoffman K, Eifel P et al. Management of advanced primary urethral carcinomas. BJU Int 2014; 114: 25-31
Meeks JJ, Taylor JM, Matsushita K et al. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int 2013; 111: E325-30
Kamoun A, de Reyniès A, Allory Y et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 2020; 77: 420-33.
Anderson C, Weber R, Patel D et al. A 10-item checklist improves reporting of critical procedural elements during transurethral resection of bladder tumor. J Urol 2016; 196: 1014-20
Sugihara T, Yasunaga H, Horiguchi H et al. Comparison of perioperative outcomes including severe bladder injury between monopolar and bipolar transurethral resection of bladder tumors: a population-based comparison. J Urol 2014; 192: 1355-9
Huang L, Kong Q, Liu Z, Wang J, Kang Z, Zhu Y. The diagnostic value of MR imaging in differentiating T staging of bladder cancer: a meta-analysis. Radiology 2018; 286: 502-11
Giannarini G, Petralia G, Thoeny HC. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 2012; 61: 326-40
Panebianco V, De Berardinis E, Barchetti G et al. An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol 2017; 27: 3759-66
Caglic I, Panebianco V, Vargas HA et al. MRI of bladder cancer: local and nodal staging. J Magn Reson Imaging 2020 [Online ahead of print]. https://doi.org/10.1002/jmri.27090
Panebianco V, Narumi Y, Altun E et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018; 74: 294-306
Barchetti G, Simone G, Ceravolo I et al. Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. Eur Radiol 2019; 29: 5498-506
Del Giudice F, Barchetti G, De Berardinis E et al. Prospective assessment of vesical imaging reporting and data system (VI-RADS) and its clinical impact on the management of high-risk non-muscle-invasive bladder cancer patients candidate for repeated transurethral resection. Eur Urol 2020; 77: 101-9
Babjuk M, Burger M, Compérat Eet al.Guidelines on Non-Muscle invasive Bladder Cancer 2020. Available at: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/.
Simone G, Papalia R, Misuraca L et al. Robotic intracorporeal Padua ileal bladder: surgical technique, perioperative, oncologic and functional outcomes. Eur Urol 2018; 73: 934-40
Koppie TM, Serio AM, Vickers AJ et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008; 112: 2384-92
Witjes JA, Bruins M, Cathomas Ret al.EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer 2020. Available at: https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.
Brausi M, Collette L, Kurth K et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41: 523-31
Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010; 57: 843-9
Russell B, Liedberg F, Khan MS et al. A systematic review and meta-analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients. Eur Urol Oncol 2020; 3: 239-49
Nieder AM, Meinbach DS, Kim SS, Soloway MS. Transurethral bladder tumor resection: intraoperative and postoperative complications in a residency setting. J Urol 2005; 174: 2307-9
Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA Jr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 2003; 170: 1085-7
Lee CT, Madii R, Daignault S et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol 2006; 175: 1262-7
May M, Nitzke T, Helke C, Vogler H, Hoschke B. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder. Scand J Urol Nephrol 2004; 38: 231-5
Sánchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003; 169: 110-5
Avallone MA, Sack BS, El-Arabi A et al. Ten-year review of perioperative complications after transurethral resection of bladder tumors: analysis of monopolar and plasmakinetic bipolar cases. J Endourol 2017; 31: 767-73
Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 2009; 115: 988-96
Poletajew S, Braticevici B, Brisuda A et al. Timing of radical cystectomy in Central Europe - multicenter study on factors influencing the time from diagnosis to radical treatment of bladder cancer patients. Cent European J Urol 2015; 68: 9-14
Busetto GM, Ferro M, Del Giudice F et al. The prognostic role of circulating tumor cells (CTC) in high-risk non-muscle-invasive bladder cancer. Clin Genitourin Cancer 2017; 15: e661-6
Nicolazzo C, Busetto GM, Gradilone A et al. Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer: updated outcome analysis of a prospective single-center trial. Oncologist 2019; 24: 612-6
Nicolazzo C, Busetto GM, Del Giudice F et al. The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). J Cancer Res Clin Oncol 2017; 143: 1971-6
Engilbertsson H, Aaltonen KE, Björnsson S et al. Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J Urol 2015; 193: 53-7
Woo S, Panebianco V, Narumi Y et al. Diagnostic performance of vesical imaging reporting and data system for the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Oncol 2020; 3: 306-15
Panebianco V, Narumi Y, Barchetti G, Montironi R, Catto JW. Should we perform multiparametric magnetic resonance imaging of the bladder before transurethral resection of bladder? time to reconsider the rules. Eur Urol 2019; 76: 57-8
Ueno Y, Takahashi S, Tamada K et al. Diagnostic accuracy and interobserver agreement for the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer: a multireader validation study. Eur Urol 2019; 76: 54-6
Wang H, Luo C, Zhang F et al. Multiparametric MRI for bladder cancer: validation of VI-RADS for the detection of detrusor muscle invasion. Radiology 2019; 291: 668-74
Kim SH. Validation of vesical imaging reporting and data system for assessing muscle invasion in bladder tumor. Abdom Radiol (NY) 2020; 45: 491-8
Makboul M, Farghaly S, Abdelkawi IF. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. Br J Radiol 2019; 92: 20190401